8:20 am Registration & Morning Refreshments

8:50 am Chair’s Opening Remark

Surveying the ADC Target Selection Space: Re-Energizing Your Development

9:00 am Utilizing Hindsight Following Progression of ADCs Into the Clinic


  • Target selection process and reasons behind the choice of pursuing various clinical targets
  • Integrin β6 – an example of Seagen’s new and promising target showing early clinical success
  • Considering reverse translation in the target selection process – lessons learned from the clinic

9:30 am Outlining Safety Advantages for Nectin-4 Relative to EphA2: Potential Benefits of Operating in a Novel Target Space

  • Steve Ludbrook Director of Molecular Pharmacology, Bicycle Therapeutics


  • Discovering the Bicycle Toxin Conjugate and potential applications in a novel target space
  • Outlining potential tolerance of less background activity
  • Discovering toxicological advancements that may lend a hand in novel target applications

10:00 am Morning Refreshments & Speed Networking


This session is the ideal opportunity to have face-to-face interactions with many of the brightest minds working in the ADC target selection field, and form meaningful business relationships

11:00 am Panel Discussion: What Is the Next Generation of ADC Targets?


  • Discussing current developments in validate ADC targets, ADC and IO combination therapy for tumor eradication rather than temporary tumor regression
  • Exploring novel targets with non-conventional (non-clathrin-mediated) internalization pathways; targets with expression in the tumor microenvironment e.g. angiogenic blood vessels
  • Discovering the future of ADC targets that can internalize to intracellular space and by passing the lysosomal payload release mechanism

11:45 am Improving ADCs Therapeutic Index With Bioconjugation & Linker Technologies


  • Benefits in Utilizing Linkers as Key Elements of ADC Design
  • Considerations on Different Linker Technologies and their Applications
  • Applying ThioBridge™ Conjugation and Linker Technology to Enhance the Efficacy Brentuximab-MMAE ADCs

12:00 pm Networking Lunch

Examining What Makes a Good ADC Target for Your Technology

1:00 pm Prevalence Of Potential Antibody Drug Conjugate (ADC) Targets With PD-L1 In Breast Cancer And Lung Cancer Patients With Clinical Response Information

  • John Cogswell Senior Group Consultant, Clinical Biomarkers, TriStar Technology Group LLC


  • Breast and Lung cancer are important diseases for antibody drug conjugate (ADC) therapeutic development with several approved in both diseases
  • Tristar ran approved IHC assays for HER2 and PD-L1 and optimized IHC assays for TROP2, NECTIN-4, B7-H3, and B7-H4 on serial slides from tissue microarrays for breast (hormone receptor positive) and non-small cell lung cancer (adeno and squamous subtypes)
  • Pathologists scored each target on the plasma membrane using approved methods for HER2 and PD-L1 and digital image analysis for percentage of tumor cells at varying intensities expressing other ADC targets. Summary data for prevalence of each target will be presented. The data may help inform where these ADC targets are highest expressed, where they overlap with respect to each other, and how expression correlates to standard of care outcomes data and their potential for combining with immunotherapies.

1:15 pm Case Study: Utilizing Hindsight Following Progression of an ADC With a HER2 Target Into the Clinic


  • Highlighting the target selection process and reasons behind the choice of pursuing HER2
  • Highlighting target and antibody considerations
  • Emphasizing challenges and successes in the development of a HER2 targeting ADC

1:45 pm More than the Sum of Their Parts: Integrating Data & Knowledge of ADCs in a QSP Platform Model to Predict Efficacy & Toxicity

  • Fei Hua PhD Vice President & Head of Mechanistic, QSP ZModeling & Simulation Services, Applied BioMath


  • We have made substantial progress towards developing a quantitative systems pharmacology platform model for ADC to predict ADC efficacy and hematological toxicities
  • We demonstrated that we can predict clinical outcome for two ADC molecules
  • The QSP platform model can be applied early on to help with target selection and predicting optimal drug properties

2:15 pm Afternoon Refreshments & Scientific Poster Session


The scientific poster session will serve as the perfect opportunity to showcase your recent work to your peers and allow you to learn and share insights in a relaxed atmosphere

Utilizing Proteomics & Bioinformatics to Aid in Target Selection

3:15 pm Discovering Novel Target Combinations for Bispecific ADCs to Increase Cancer Selectivity

  • Stefan Ries Chief Scientific Officer, R&D, DISCO Pharmaceuticals


  • Identifying cell surface proteins for bispecific targeting of cancer cells
  • Outlining benefits of utilizing bispecific ADCs to increase the therapeutic index
  • Unique challenges to overcome when designing bispecific ADCs

3:45 pm Clarifying What Level of Expression Is Actually Good for ADC Target Selection?


  • How important is cell surface receptor density in the in vitro efficacy of ADCs?
  • Is bystander activity important for an ADC payload and how do you evaluate ADC bystander activity?
  • Can bispecific ADCs address heterogeneous tumor expression of ADC targets?

4:15 pm End of Conference Day One